Arsanis, Inc., a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, announced the closing of its initial public offering of 4,600,000 shares of its common stock at a public offering price of $10 per share, including 600,000 additional shares of common stock issued upon the exercise in full by the underwriters of their over-allotment option. The gross proceeds to Arsanis from the offering were $46 million, before deducting underwriting discounts and commissions and other offering expenses.
 
In addition, a fund affiliated with New Enterprise Associates purchased $20 million of Arsanis' common stock in a separate private placement concurrent with the completion of Arsanis' initial public offering at a price per share equal to the initial public offering price.
 
The WilmerHale team representing Arsanis included Steven Singer, Cynthia Mazareas, Jeffries Oliver-Li, Mhairi Immermann and Hayley Ryan.
 
Read Arsanis' press release to learn more.